Needham & Company LLC Reaffirms Hold Rating for Omeros (NASDAQ:OMER)

Omeros (NASDAQ:OMER)‘s stock had its “hold” rating reaffirmed by equities researchers at Needham & Company LLC in a research note issued to investors on Tuesday,Benzinga reports.

OMER has been the topic of a number of other research reports. StockNews.com cut shares of Omeros from a “hold” rating to a “sell” rating in a research note on Friday, March 21st. D. Boral Capital restated a “buy” rating and set a $36.00 price target on shares of Omeros in a research report on Tuesday. One analyst has rated the stock with a sell rating, two have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Trading Up 1.4 %

OMER traded up $0.12 during midday trading on Tuesday, hitting $8.34. 534,664 shares of the company were exchanged, compared to its average volume of 540,716. The company’s 50 day simple moving average is $8.66 and its 200 day simple moving average is $7.58. The firm has a market capitalization of $483.01 million, a price-to-earnings ratio of -3.60 and a beta of 2.03. Omeros has a 1-year low of $2.61 and a 1-year high of $13.60.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Two Sigma Investments LP increased its holdings in Omeros by 8.8% in the 4th quarter. Two Sigma Investments LP now owns 162,991 shares of the biopharmaceutical company’s stock worth $1,610,000 after acquiring an additional 13,201 shares in the last quarter. ProShare Advisors LLC increased its stake in shares of Omeros by 75.0% during the fourth quarter. ProShare Advisors LLC now owns 18,496 shares of the biopharmaceutical company’s stock worth $183,000 after purchasing an additional 7,927 shares in the last quarter. Nomura Holdings Inc. increased its stake in shares of Omeros by 136.2% during the fourth quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company’s stock worth $7,383,000 after purchasing an additional 430,932 shares in the last quarter. Millennium Management LLC raised its position in shares of Omeros by 46.2% during the 4th quarter. Millennium Management LLC now owns 85,671 shares of the biopharmaceutical company’s stock worth $846,000 after purchasing an additional 27,088 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Omeros by 3.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,831 shares of the biopharmaceutical company’s stock worth $314,000 after buying an additional 1,110 shares during the last quarter. 48.79% of the stock is owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.